Compared with glycoprotein IIb/IIIa inhibitors (GPIs), the antithrombin agent bivalirudin reduces the risk of bleeding complications in patients with ST-segment elevation myocardial infarction (STEMI) ...

WASHINGTON, DC—After years of randomized and observational trials and several meta-analyses, there still seems to be no consensus among interventionalists as to whether bivalirudin or heparin is the ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. “The mortality benefit of bivalirudin in STEMI patients ...

CHICAGO -- Periprocedural anticoagulation with bivalirudin (Angiomax) for a radial-first approach to primary percutaneous coronary intervention (PCI) improved mortality and bleeding risk compared with ...

Treatment with the direct thrombin inhibitor bivalirudin, as compared with heparin plus glycoprotein IIb/IIIa inhibitors, results in similar suppression of ischemia while reducing hemorrhagic ...

As recently as November 2002, substantial data supporting the use of bivalirudin in a modern interventional practice were not available. Two multicenter, double-blind, controlled, randomized clinical ...

Auckland, New Zealand - Bivalirudin (Angiomax? - The Medicines Company) should be considered as a new anticoagulant treatment option in patients with acute MI (AMI) treated with streptokinase, ...

Please provide your email address to receive an email when new articles are posted on . Among patients with ACS who received an infusion of bivalirudin after PCI, those who had a full dose showed ...

Discover comprehensive details about Bivalirudin, including its pronunciation, uses, dosage instructions, indications, and guidelines on how and when to take it or avoid it. The updated prescription ...

Review the side-effects of Bivalirudin as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...

An analysis of all of the previous trials to date has been conducted to better define both the benefits and risks of the competing anticoagulants. Researchers found that, compared with heparin-based ...

The comparative efficacy of various anticoagulation strategies has not been clearly established in patients with acute myocardial infarction who are undergoing percutaneous coronary intervention (PCI) ...